Loading...
•
Mar 31
Curis Q1 2025 Earnings Report
Curis reported its business update and financial results for the first quarter ended March 31, 2025.
Key Takeaways
Curis reported a net loss of $10.6 million for the first quarter of 2025, an improvement from the $11.9 million net loss in the same period of 2024. Revenues increased to $2.4 million from $2.1 million year-over-year, primarily driven by royalty revenues from Erivedge® sales. The company also announced the appointment of Dr. Ahmed Hamdy as Chief Medical Officer and made progress with regulatory discussions for emavusertib.
Net loss improved to $10.6 million in Q1 2025 from $11.9 million in Q1 2024.
Revenues increased to $2.4 million in Q1 2025 from $2.1 million in Q1 2024, primarily from Erivedge® royalties.
Dr. Ahmed Hamdy was appointed as the new Chief Medical Officer, strengthening the executive team.
Significant progress was made with FDA and EMA regarding accelerated approval for emavusertib in R/R PCNSL, with ongoing patient enrollment in the TakeAim Lymphoma study.
Curis
Curis
Curis Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.com Forward Guidance
Curis expects its existing cash and cash equivalents to fund operations into the fourth quarter of 2025. The company is pursuing accelerated approval for emavusertib in PCNSL in both the EU and US, with additional data expected later this year. However, significant additional funding will be required for continued development and commercialization.
Positive Outlook
- Existing cash and cash equivalents are expected to enable planned operations into the fourth quarter of 2025.
- Progress with FDA and EMA on potential accelerated approval for emavusertib in R/R PCNSL.
- Expectation to provide additional data for BTK-naïve and BTK-experienced patients from the TakeAim Lymphoma study at ASH later this year.
- Emavusertib has received Orphan Drug Designation for PCNSL in both the U.S. and Europe.
- Successful completion of the first dosing cohort and commencement of dosing in the second cohort for the Ema-Ven-Aza Triplet Study in Frontline AML.
Challenges Ahead
- Curis will require substantial additional capital to fund its business beyond Q4 2025.
- Inability to obtain sufficient funding could lead to delays, scope reduction, or elimination of drug development programs.
- Risk of adverse decisions from regulatory authorities, investigational review boards, and publication review bodies.
- Potential for unexpected toxicities or insufficient safety and efficacy in clinical studies.
- Unstable market and economic conditions, natural disasters, public health crises, and political crises could significantly disrupt operations.